Dr Monroe will lead the company’s efforts to develop and commercialize image analysis applications to provide customers with the most comprehensive panels for breast, prostate, lung, colon pathology as well as cytopathology.
He has over 10 years of pathology and research experience and his appointment follows the recent funding round where BioImagene raised $26 million for expansion capital and expanded its board.
Mohan Uttarwar, BioImagene CEO, said: “Dr Monroe’s appointment is a significant step in expanding our lead in technology innovation and broadening our suite of image analysis algorithms. We welcome him on board and eagerly anticipate his contribution towards expanding our digital pathology applications developed for pathologists, by combining innovations in image processing with deep knowledge of pathology.”